Skip to main content
Top

26-10-2016 | Sarcoma | Article

Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma

Journal: Annals of Surgical Oncology

Authors: Brett L. Ecker, MD, Madalyn G. Peters, MD, Matthew T. McMillan, BA, Andrew J. Sinnamon, MD, Paul J. Zhang, MD, Rachel R. Kelz, MD, Robert E. Roses, MD, Jeffrey A. Drebin, MD, PhD, Douglas L. Fraker, MD, Giorgos C. Karakousis, MD

Publisher: Springer International Publishing

Abstract

Background

The rate of lymph node (LN) metastasis is rare in soft tissue sarcoma, but there are histologic subtypes that metastasize via the lymphatics. The prognostic value of LN evaluation in these high-risk histologies is unknown.

Methods

Resected soft-tissue sarcoma patients with clear cell sarcoma, epithelioid sarcoma, rhabdomyosarcoma, or angiosarcoma (n = 2993) were identified in the National Cancer Data Base (2004–2013). Cox regression evaluated the association of omission of LN assessment (NX) and overall survival (OS). Subjects who underwent surgical resection with or without regional LN evaluation were matched (1:1) by propensity scores based on the likelihood of NX or survival hazard on Cox modeling. OS was compared by Kaplan–Meier estimates.

Results

A total of 637 (21.3%) underwent LN evaluation and 176 (5.9%) were found to have nodal metastasis. Omission of nodal evaluation was significantly associated with risk of death (reference: N0; N+: hazard ratio [HR] 1.46, 95% confidence interval [CI] 1.11–1.91; NX: OR 1.18, 95% CI 1.00–1.40). After propensity score matching, there was a significant difference in median OS following pathologic identification of nodal disease for epithelioid sarcoma (N0: not reached vs. N+: 55.9 months vs. NX: not reached, p = 0.001) and clear cell sarcoma (N0: not reached vs. N+: 20.0 months vs. NX: 95.0 months, p < 0.001).

Conclusions

These data support more standardized approaches to regional lymph node examination for patients with epithelioid and possibly clear cell sarcoma and provide compelling evidence that nodal evaluation can be considered a quality measure in the delivery of cancer care for certain sarcoma subtypes.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRefPubMed
2.
Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008;15(10),2739–48.CrossRefPubMed
3.
Stojadinovic A, Leung DH, Hoos A, et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235(3):424–34.CrossRefPubMedPubMedCentral
4.
Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.PubMed
5.
Strander H, Turesson I, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol. 2003;42(5–6):516–31.CrossRefPubMed
6.
Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335–46.PubMed
7.
MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457–60.CrossRefPubMed
8.
Ecker BL, Paulson EC, Datta J, et al. Lymph node identification following neoadjuvant therapy in rectal cancer: a stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database. J Surg Oncol. 2015;112(4):415–20.CrossRefPubMed
9.
Datta J, Lewis RS Jr, Mamtani R, et al. Implications of inadequate lymph node staging in resectable gastric cancer: a contemporary analysis using the National Cancer Data Base. Cancer. 2014;120(18):2855–65.CrossRefPubMed
10.
Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMed
11.
Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.CrossRefPubMed
12.
Datta J, McMillan MT, Ecker BL, et al. Implications of lymph node staging on selection of adjuvant therapy for gastric cancer in the United States: a propensity score-matched analysis. Ann Surg. 2016;263(2):298–305.CrossRefPubMed
13.
Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60:1800–8.CrossRefPubMed
14.
Weingrad DN, Rosenberg SA. Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery. 1978;84(2):231–40.PubMed
15.
Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004;(426):129–34.CrossRef
16.
Johannesmeyer D, Smith V, Cole DJ, et al. The impact of lymph node disease in extremity soft-tissue sarcomas: a population-based analysis. Am J Surg. 2013;206(3):289–95.CrossRefPubMed
17.
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Soft tissue sarcoma (version 2.2016). http://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​sarcoma.​pdf. Accessed 28 Mar 2016.
18.
Fong Y, Coit DG, Woodruff JM, et al. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72–7.CrossRefPubMedPubMedCentral
19.
Sherman KL, Kinnier CV, Farina DA, et al. Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma. J Surg Oncol. 2014;110(6):682–88.CrossRefPubMed
20.
Bilimoria K, Stewart A, Winchester D, Ko CY. The national cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.CrossRefPubMedPubMedCentral
21.
Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014; 33:1242–58.CrossRefPubMed
22.
World Health Organization. International classification of disease for oncology. 3rd ed. Geneva: World Health Organization; 2000.
23.
Robb WB, Dahan L, Mornex F, et al. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2015;261(5):902–8.CrossRefPubMed
24.
Miller ED, Robb BW, Cummings OW, et al. The effects of preoperative chemoradiotherapy on lymph node sampling in rectal cancer. Dis Colon Rectum. 2012;55(9):1002–7.CrossRefPubMed
25.
Ecker BL, McMillan MT, Datta J, et al. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: a propensity score-matched analysis. Cancer. 2016;122(5):693–701.CrossRefPubMed
26.
Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27:2037–49.CrossRefPubMed
27.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.CrossRefPubMedPubMedCentral
28.
Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013; 32:2837–49.CrossRefPubMed
29.
Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011; 10:150–61.CrossRefPubMed
30.
Howlader N, Noone AM, Krapcho M, et al. (eds). SEER cancer statistics review, 1975–2012, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2012/​, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
31.
Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008; 248:221–6.CrossRefPubMed
32.
Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup Trial INT-0089. J Clin Oncol. 2003; 21:2912–9.CrossRefPubMed
33.
Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005; 23:7114–24.CrossRefPubMed
34.
Maduekwe UN, Hornicek FJ, Springfield DS, et al. Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol. 2009;16(5):1356–63.CrossRefPubMed
35.
Tunn PU, Andreou D, Illing H, et al. Sentinel node biopsy in synovial sarcoma. Eur J Surg Oncol. 2008;34:704–7.CrossRefPubMed
36.
Al-Refaie WB, Andtbacka RH, Ensor J, et al. Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. Cancer. 2008;112(8):1821–6.CrossRefPubMed
37.
Behranwala KA, A’Hern R, Omar AM, et al. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol. 2004;11(7):714–9.CrossRefPubMed
38.
Greene F, Page D, Fleming F, et al. American Joint Committee on Cancer: cancer staging manual. 6th edn. New York: Springer; 2002:221–6.CrossRef
39.
Edge S, Byrd, DR, Compton CC, et al. American Joint Committee on Cancer: cancer staging manual. 7th edn. New York: Springer; 2010.
40.
Wright S, Armeson K, Hill EG, et al. The role of sentinel lymph node biopsy in select sarcoma patients: a meta-analysis. Am J Surg. 2012;204(4):428–33.CrossRefPubMed
41.
Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13(4):533–41.CrossRefPubMed
42.
Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912–8.CrossRefPubMed